Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective

被引：29

作者：

Trudel, Sabrina ^{[1
]}

Moreau, Philippe ^{[1
,2
,3
]}

Touzeau, Cyrille ^{[1
,2
,3
]}

机构：

[1] Univ Hosp, Hematol Dept, Pl Alexis Ricordeau, F-44093 Nantes, France

[2] Univ Nantes, Univ Angers, CRCINA, INSERM,CNRS, Nantes, France

[3] Imaging & Longitudinal Invest Ameliorate Decis Ma, Site Rech Integree Canc SIRIC, Nantes, France

来源：

ONCOTARGETS AND THERAPY | 2019年 / 12卷

关键词：

CS1; SLAMF7; elotuzumab; monoclonal antibody; multiple myeloma; LOW-DOSE DEXAMETHASONE; OPEN-LABEL; IMMUNOMODULATORY DRUGS; LENALIDOMIDE; CARFILZOMIB; DARATUMUMAB; PHASE-2; POMALIDOMIDE; MULTICENTER; COMBINATION;

D O I：

10.2147/OTT.S174640

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Monoclonal antibodies (mAbs) targeting antigens expressed by plasma cells demonstrated major clinical activity in multiple myeloma patients and therefore became a new major class of drug for these patients. Elotuzumab is a humanized mAb targeting the cell surface signaling lymphocytic activation molecule family member 7, a glycoprotein highly expressed on plasma cells, that is the second mAb approved for the treatment of myeloma patients. The mechanism of action of elotuzumab includes natural killer cell (NK) mediated antibody-dependent cellular cytotoxicity and direct activation of NK-cells. Elotuzumab has been approved in combination with lenalidomide and dexamethasone (EloRd) and pomalidomide and dexamethasone (Elo-Pd) for the treatment of relapsed myeloma patients. The present review will focus on elotuzumab, providing a summary of the mechanism of action, efficacy and safety and taking into consideration patients' selection.

引用

页码：5813 / 5822

页数：10

共 46 条

[1]

[Anonymous], BLOOD

[2]

[Anonymous], BLOOD S1

[3] Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma [J].

Baz, Rachid C. ;

Martin, Thomas G., III ;

Lin, Hui-Yi ;

Zhao, Xiuhua ;

Shain, Kenneth H. ;

Cho, Hearn J. ;

Wolf, Jeffrey L. ;

Mahindra, Anuj ;

Chari, Ajai ;

Sullivan, Daniel M. ;

Nardelli, Lisa A. ;

Lau, Kenneth ;

Alsina, Melissa ;

Jagannath, Sundar .

BLOOD, 2016, 127 (21) :2561-2568

[4] Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study [J].

Berdeja, Jesus ;

Jagannath, Sunday ;

Zonder, Jeffrey ;

Badros, Ashraf ;

Kaufman, Jonathan L. ;

Manges, Robert ;

Gupta, Manish ;

Tendolkar, Amol ;

Lynch, Mark ;

Bleickardt, Eric ;

Paliwal, Prashni ;

Vij, Ravi .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (03) :129-138

[5] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study [J].

Bringhen, Sara ;

Mina, Roberto ;

Cafro, Anna Maria ;

Liberati, Anna Marina ;

Spada, Stefano ;

Belotti, Angelo ;

Gaidano, Gianluca ;

Patriarca, Francesca ;

Troia, Rossella ;

Fanin, Renato ;

De Paoli, Lorenzo ;

Rossi, Giuseppe ;

Lombardo, Alessandra ;

Bertazzoni, Paola ;

Palumbo, Antonio ;

Sonneveld, Pieter ;

Boccadoro, Mario .

LEUKEMIA, 2018, 32 (08) :1803-1807

[6] Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study [J].

Cella, David ;

McKendrick, Jan ;

Kudlac, Amber ;

Palumbo, Antonio ;

Oukessou, Abderrahim ;

Vij, Ravi ;

Zyczynski, Teresa ;

Davis, Catherine .

ANNALS OF HEMATOLOGY, 2018, 97 (12) :2455-2463

[7] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

[8] Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, Meletios A. ;

Dytfeld, Dominik ;

Grosicki, Sebastian ;

Moreau, Philippe ;

Takezako, Naoki ;

Hori, Mitsuo ;

Leleu, Xavier ;

LeBlanc, Richard ;

Suzuki, Kenshi ;

Raab, Marc S. ;

Richardson, Paul G. ;

McKiver, Mihaela Popa ;

Jou, Ying-Ming ;

Shelat, Suresh G. ;

Robbins, Michael ;

Rafferty, Brian ;

San-Miguel, Jesus .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19) :1811-1822

[9] Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial [J].

Dimopoulos, Meletios A. ;

Lonial, Sagar ;

Betts, Keith A. ;

Chen, Clara ;

Zichlin, Miriam L. ;

Brun, Alexander ;

Signorovitch, James E. ;

Makenbaeva, Dinara ;

Mekan, Sabeen ;

Sy, Oumar ;

Weisel, Katja ;

Richardson, Paul G. .

CANCER, 2018, 124 (20) :4032-4043

[10] Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial [J].

Dimopoulos, Meletios A. ;

Goldschmidt, Hartmut ;

Niesvizky, Ruben ;

Joshua, Douglas ;

Chng, Wee-Joo ;

Oriol, Albert ;

Orlowski, Robert Z. ;

Ludwig, Heinz ;

Facon, Thierry ;

Hajek, Roman ;

Weisel, Katja ;

Hungria, Vania ;

Minuk, Leonard ;

Feng, Shibao ;

Zahlten-Kumeli, Anita ;

Kimball, Amy S. ;

Moreau, Philippe .

LANCET ONCOLOGY, 2017, 18 (10) :1327-1337

← 1 2 3 4 5 →